- Open Access
Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study
© Li et al.; licensee BioMed Central Ltd. 2014
- Received: 1 April 2014
- Accepted: 14 July 2014
- Published: 22 July 2014
Alternatives to treatment for malaria treatment of travellers are needed in the USA and in Europe for travellers who return with severe malaria infections. The objective of this study is to show the pharmacokinetic (PK) profile of intravenous artesunate (AS), which was manufactured under good manufacturing practice (GMP) conditions, in adults with uncomplicated falciparum malaria in Kenya.
The PK parameters of intravenous AS manufactured under current cGMP were evaluated after a single dose of drug at 2.4 mg/kg infused over 2 min in 28 adults with uncomplicated Plasmodium falciparum malaria. Plasma concentrations of AS and dihydroartemisinin (DHA) were measured using a validated liquid chromatography–mass spectrometry (LC-MS/MS) methodology. Pharmacokinetic data were analysed with a compartmental analysis for AS and DHA.
The results suggest there were no drug-related adverse events in any of the patients. After intravenous infusion, the concentration of the parent drug rapidly declined, and the AS was converted to DHA. AS and DHA showed mean elimination half-lives of 0.17 hours and 1.30 hours, respectively. The high mean peak concentration (Cmax) of AS was shown to be 28,558 ng/mL while the Cmax of DHA was determined to be 2,932 ng/mL. Significant variability was noted in the PK profiles of the 28 patients tested. For example, Cmax values of AS were calculated to range from 3,362 to 55,873 ng/mL, and the Cmax value of DHA was noted to vary from 1,493 to 5,569 ng/mL. The mean area under the curve (AUC) of AS was shown to be approximately half that of DHA (1,878 ng·h/mL vs 3,543 ng·h/mL). The DHA/AS ratio observed was 1.94 during the one-day single treatment, and the AUC and half- life measured for DHA were significantly larger and longer than for AS.
Intravenous AS can provide much higher peak concentrations of AS when compared to concentrations achieved with oral therapy; this may be crucial for the rapid elimination of parasites in patients with severe malaria. Given the much longer half-life of DHA compared to the short half-life of AS, DHA also plays a significant role in treatment of severe malaria.
- Uncomplicated falciparum malaria
- Clinical trial
Intravenous (IV) artesunate (AS) has been shown to completely inhibit parasite growth in infected human patients within two to four hours after dosing, and its active metabolite, dihydroartemisinin (DHA), is the only artemisinin derivative with activity against all asexual blood stage parasites. AS treatment results in rapid parasite and fever clearance, and these effects have been mostly attributed to its rapid and extensive hydrolysis to DHA[2–4], the most active schizonticidal metabolite. In vitro bioassay tests have shown that the activity of DHA is similar to AS and three- to five-fold more active than other artemisinin derivatives[6, 7]. AS has been shown to be highly effective against multidrug-resistant falciparum malaria and for treatment of severe malaria in Vietnam, Thailand, China, and Myanmar, however, limited studies have been carried out in Africa. Currently, there are three recommended treatments for severe and complicated malaria: AS, artemether (AM) and quinine (or quinidine). The Chinese manufacturer (Guilin Pharmaceutical Co Ltd, Shanghai, China) of the injectable AS that was used in most of the clinical trial studies recently improved its production process, with support from Medicine for Malaria Venture (MMV), and their product has achieved World Health Organization (WHO) recognition. Intravenous quinine or quinidine, however, is still used in Europe and the USA as the main barrier for the use of intravenous AS is the absence of an approved product that is manufactured under good manufacturing practices (GMP) and is legally available in these regions for patient treatment.
Following recent clinical studies with severe malaria patients, IV AS was shown to have the highest success for treatment of malaria with a low incidence of adverse events[10–12]. The two largest trials ever conducted for severe malaria in endemic regions showed that, in both adults and children, treatment with IV AS yields better outcomes than treatment with IV quinine. The mortality rate among quinine-treated patients was shown to be 22 and 10.9% in the Southeast Asia Quinine Artesunate Malarial Trial (SEAQUAMAT) and Africa Quinine Artesunate Malarial Trial (AQUAMAT) studies, respectively, and the mortality rate among AS-treated patients was shown to be 15 and 8.5%, respectively. When comparing the mortality rates achieved with treatment of these two drugs, AS reduced mortality by 35% in the SEAQUAMAT trial and 22.5% in the AQUAMAT trail. Patients with hyperparasitaemia (>10% of red blood cells (RBC) experienced a significantly greater treatment effect after AS treatment than patients that did not have hyperparasitaemia. IV AS was also shown to be better tolerated, safer and easier to use than quinine. The life-saving benefit of AS for treatment of severe malaria was recognized by the WHO in 2010, and since then IV AS has been the initial treatment of choice for patients with severe falciparum malaria infections[11, 12].
Alternatives to treatment for severe malaria are needed in the USA and Europe for treatment of severe malaria. While nations in the Third World can choose to use AS preparations such as the Guilin AS product for treatment of disease, there are issues with the use of this AS product in First World countries where the Guilin AS formulation cannot be sold legally. The objective of this study is to show the pharmacokinetic (PK) profile of IV AS in Kenyans infected with uncomplicated falciparum malaria. The PK estimates will be also used to compare with the PK profiles observed in populations of healthy adults administered AS in another manuscript. The overall goal in the present study was to provide a well-validated, efficacious, and safe product for the treatment of severe malaria licensed by the US Food and Drug Administration (FDA) available for use in the USA and by US soldiers who encounter severe malaria infections.
The bulk artesunic acid (4-(10’dihydro-artemisinin-oxymethyl) succinate) substance was purchased from Knoll AG (Switzerland). BASF Pharmaceuticals rebottled it from the original company under GMP conditions. The clinical trial AS (Batch #: 14462–16) was tested for sterility and short-term stability. The formulation was contained in sterilized bottles with 110 mg artesunic acid per bottle. The injection buffer for AS was manufactured as a GMP phosphate salt with 0.3 M PBS (pH 8.0). The product was prepared for administration by reconstitution in sodium phosphate buffer prior to infusion, which took place within 1 hr after solution was prepared due to a precipitation in 3–4 hours at room temperature.
All subjects gave written informed consent prior to the commencement of any study procedure (e.g, blood smear). Overall, 30 adult subjects were enrolled, 20 males and ten non-pregnant females, aged 18–65 years, with uncomplicated Plasmodium falciparum malaria and body weights of 42–85 kg. The subjects of this study resided in a malaria-endemic region of Kenya and in districts surrounding the Province of Nyanza. The majority of the population in these areas is considered semi-immune, however, malaria attack rates in the city are low, and many adults in this area may well have waning immunity. The prevalence of malaria in Nyanza Province has been shown to range from 25 to 45%.
Adult subjects were recruited with signs and symptoms of malaria who were seen at the Nyanza Medical Centre, Kisumu or one of its neighbouring health clinics (Kisumu District Hospital in Kisumu; Nyahera Health Centre, Rabuor Dispensary, in Kisumu, and Kombewa Subdistrict Hospital), Nyanza Province. Local clinicians made a provisional clinical diagnosis of malaria, and these patients were subsequently referred to the hospital laboratory for microscopic examination of blood smears or rapid malaria antigen tests. Those subjects from the hospital laboratory who had not initiated therapy after a positive test were recruited for this study.
The screening process for subject participation consisted of questionnaires and clinical examinations including medical history, physical examination, and laboratory analyses. Phlebotomy was performed to obtain samples for laboratory testing and malaria blood films. A clean-catch urine specimen was also collected for urinalysis and pregnancy testing, as applicable. Baseline safety testing included both clinical chemistry and haematology testing. Analyses included blood urea nitrogen (BUN), creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total and direct bilirubin, reticulocyte, and a complete blood cell (CBC) count with differential assessment. Ultimately, enrolment determinations consisted of compliance with inclusion and exclusion criteria, including a diagnosis of uncomplicated P. falciparum malaria with at least 200 parasites per μL confirmed by malaria blood smear.
This was a Phase II, open-label, non-randomized PK clinical trial of IV AS. Subjects completed an outpatient visit at the study centre for confirmation of study eligibility and baseline electrocardiogram monitoring. All subjects received an identical dose of the test article: injectable IV AS daily for two days consisting of 2.4 mg/kg delivered over 2 min. Safety, PK and efficacy assessments occurred intermittently with follow-on standard therapy with a three-day course of Malarone® to ensure cure. After completion of each injection, the study nurse examined how well AS injection was tolerated by performing inspection of the injection site and subject response. Normal activities, excluding strenuous exercise, were permitted four hours after dosing. The clinical trial identifier in ClinicalTrials.gov is NCT00298610. The human use protocol numbers for this Phase II trial are Uniformed Services University of the Health Sciences (USUHS) #G183RW; Walter Reed Army Institute of Research (WRIAR) #1128; Human Subjects Research Review Board (HSRRB) #A13331, and the Kenya Medical Research Institute (KEMRI) #917.
PK and finger-stick sampling
PK sampling was performed using a flush saline technique from an IV line or phlebotomy if the IV line was compromised. Samples were collected on day 1 approximately 10 min before dosing (0 hours), and at the following nominal time points after dosing: 5, 10, 20, and 40 min, and 1, 2, 4, and 6 hours. The blood (6 ml) will be collected from each subject via a cannula or by repeated venipuncture (opposite arm from infusion) into lithium heparin tubes. Actual time points were obtained within ± 20% of the stated time points, and the plasma samples were immediately stored at approximately −70°C after collection, and shipped to the Armed Forces Research Institute of Medical Sciences (AFRIMS) Bangkok, Thailand on dry ice, for analysis. Finger-stick sampling was used for any malaria blood films collected at time points not requiring phlebotomy.
Treatment and monitoring
Subjects were treated and monitored as outpatients or inpatients as deemed necessary by the subject, study staff and the principal investigator. Subjects managed as outpatients were permitted to leave the study site after the first dose of study drug (day 0) and sampling (approximately eight hours). Subjects were required to return the following day for scheduled follow-up.
An LC-MS method for the quantitation of AS and DHA (100 μL) in human plasma was validated in a range from 1.4-1,153 ng/mL for AS and from 1.1-853 ng/mL for DHA. The analytes were extracted from human plasma after protein precipitation using two volumes of ice-cold acetonitrile. After centrifugation at 10,000 rpm, the clear supernatant extracts were analysed on a single quadrupole Mass Spectrometer (Micromass ZQ, MM1, Waters Corp, Milford, MA, USA) in the positive ion electrospray ionization (+ESI) mode. The AS and DHA compounds were monitored using single ion recording. The LC-MS with a reversed phase column (XTerra MS C18, 3.5 μm, 2.1 × 50 mm) and a pre-column of the same material (2.1 × 10 mm) was mounted on a liquid chromatography system (Alliance 2695, Waters Corp, Milford, MA, USA). The method was performed a gradient elution with the following mobile phases: A) 6.25 mM ammonium acetate in water (pH 4.5) and B) 100% acetonitrile gradient from 20 to 40% in ammonium acetate buffer in 9 min at the flow rate of 0.4 mL/min. The ammonium-adducts of DHA were detected at a mass to charge ratio (m/z) of 302 and eluted in 5 min, while adducts of AS were detected at a mass to charge ratio of 402 and eluted in 6 min. The total analysis time for both compounds was 12 min.
In these methods, the intra-assay and inter-assay accuracy and precision (n = 6) had an inaccuracy rate of ± 8.4% and coefficient of variations (CVs) of ≤7.9% at 19.2/14.2 (50), 192/142 (500), 961/711 (2,500) and 1,153/853 (3,000) ng/mL (nM) for AS/DHA. The intra-assay and inter-assay inaccuracy and precision were within ± 6.0 and ≤17.6%, respectively. Standard curve and quality control (QC) samples were generated by spiking interference-free human plasma samples with known amounts of AS, DHA and internal standard. The drug concentrations of the QC samples chosen were within the range of the standard curve, and included a low (<3 × LLOQ), medium, and high QC levels. The lower limit of quantitation (LLOQ) was 1.44/1.07 (3.75) ng/mL (nM) for AS/DHA. Any out-of-trend concentration values were re-analysed with the average of three repeated values used in PK parameter determination. Calibration standards and QC samples were analysed to evaluate the performance of the assay and were the same as the validated method previously described.
In order to compare only the clinically relevant AS concentrations, a compartmental PK analysis was based on a short-term (2 min) IV infusion on individual patient level in accordance with a previous PK evaluation[15, 16]. The disposition of injectable AS was best described by a two-compartment model with a rapid initial distribution phase after IV administration. The input of the drug was assumed to follow zero-order kinetics, and elimination from the central compartment occurred with first-order kinetics. compartmental analysis (CA) of concentration-time data for AS was performed by using the Phoenix-WinNonlin software Version 6.3 (Pharsight Corp, Mountain View, CA, USA) with an IV infusion programme. The first-order method with logarithmic transformation of all drug-concentration data was used throughout.
The drug plasma concentrations at the end of IV infusion (Cmax) were calculated from the corresponding model equations (IV-infusion model, WinNonlin) at the respective time points. The AUCinf was estimated by direct integration of equation with CA modeling from zero to infinity. The total clearance (CL) is calculated with dose divided by total AUC. The Cmax and the time to maximum drug concentration (Tmax) were obtained from the PK modeling. The predicted AS concentration at the end of the infusion (2 min), however, was calculated by compartmental modelling. The values of the following PK parameters were derived by a compartmental method. The elimination half-life (t½), mean residence time (MRT), the AUC from time zero to the last sampling time (AUCt), the AUC from time zero extrapolated to infinity (AUCinf), total systemic clearance (CL), and the volume of distribution during steady state (Vss) were obtained by PK modeling.
Previous PK analysis and PK estimates in the present study confirmed that the PK parameters of DHA are similar when using the non-compartmental analysis (NCA) and CA analyses, suggesting that PK modelling of DHA is model-independent. Thus, the both methods are suitable for DHA. The values of the following PK parameters were derived by a compartmental method with the Cmax, t½, MRT, AUCinf, relative total systemic clearance (CL/F), and the volume of distribution during steady state (Vss/F). The AUCinf ratios of AS to its metabolite (DHA) were calculated to determine exposure to any metabolite compared with the parent drug.
IV AS manufactured to be cGMP compliant was administrated to 30 adult patients. PK samples were not collected for two subjects (Two cases have been excluded due to the insufficient data). Efficacy and safety evaluations will be discussed in detail in a separate manuscript.
Safety and tolerability
In this study, 30 patients with uncomplicated P. falciparum malaria were treated with an intravenous infusion of AS (2.4 mg/kg given over 2 min) daily for two days. For each subject, adverse events (AEs) were recorded throughout the post-dosing period. Multiple doses of this formulation of AS administered intravenously at a dose of 2.4 mg/kg daily for two consecutive days were well tolerated in all patients. No dose related toxicity was found for AS at the doses studied. There were no subject dropouts for AEs or other treatment-related issues. The dose-related decrease in reticulocyte count was noted that reached its lowest point four days after dosing and returned to normal by study day 7 in most cases. There were no other clinically significant laboratory abnormalities detected. No deleterious haemodynamic or electrocardiography (ECG) effects were seen. A transient, reversible sensation of altered or unusual taste, which lasted less than 30 min in all cases, was associated with intravenous dosing of AS. All remaining side effects were generally mild and all were reversible.
Pharmacokinetics of AS and DHA
Mean pharmacokinetic parameters of artesunate (AS) and its active metabolite dihydroartemisinin (DHA) after pharmacokinetic modelling by using compartment analysis with IV-infusion fitting for AS following single intravenous infusion (2 minutes) at single dose of 2.4 mg/kg in the adults with uncomplicated falciparum malaria in Kenya (n = 28)
PK parameters artesunate
CA IV-infusion (PK model 9)
PK parameters dihydroartemisinin
CA analysis (PK model 14)
28,558 ± 28,531
2,932 ± 850
0.028 ± 0.015
0.18 ± 0.06
AUCinf (ng · h/mL)
1,879 ± 1,190
AUCinf (ng · h/mL)
3,543 ± 989
t1/2 distribution (h)
0.05 ± 0.01
0.13 ± 0.05
t1/2 elimination (h)
0.17 ± 0.08
1.30 ± 0.34
1,728 ± 983
731 ± 205
139 ± 124
1,048 ± 250
0.07 ± 0.02
1.61 ± 0.44
Ratio of AUCDHA/AS
1.94 ± 1.16
Ratio of CmaxAS/DHA
10.24 ± 7.61
Ratio of t1/2 DHA/AS
7.65 ± 3.16
Variable PK profiles of AS and DHA
In the 28 malaria patients evaluated in this study, the peak concentrations (Cmax) of AS following IV infusion ranged from 3,362 to 55,873 ng/mL, and the AUC of AS ranged from 477 to 6,434 ng · h/mL, suggesting a large inter-individual variability in these PK parameters. Similarly, the Cmax of DHA ranged from 1,493 to 5,569 ng/mL, and the AUC values calculated ranged from 2,024 to 5,424 ng · h/mL.
The concentration of DHA, which was converted from AS, was also shown to be highly variable in the 28 patients evaluated. The ratio of AUCDHA/AS ranged from 0.72 to 4.16 (Table 1). In addition, the AUC of DHA was significantly higher than the AUC of AS with a mean AUCDHA/AS ratio of 1.94, however, the peak concentration of AS was much higher than that of DHA with a mean CmaxAS/DHA ratio of 10.24. DHA was also shown to have a 7.65-fold longer elimination half-life than AS.
IV AS has been used to treat patients with both uncomplicated P. falciparum and severe malaria for more than 25 years. Artesunate has been shown to be highly effective against multidrug resistant falciparum malaria and for treatment of severe malaria in Asia. However, the main barrier for the use of intravenous AS in Western countries is the absence of an approved product manufactured under GMP. A major concern that has been expressed is that the currently available AS products available for use are not available in Western countries for treatment of travellers with severe malaria because they are not licensed for use in either Europe or the USA. While there is no evidence in clinical trials conducted to date that the absence of GMP-produced AS translates into reduced efficacy, there are significant long-term benefits to patient care associated with implementing a licensed GMP artesunate product that is available for treatment of travellers with severe malaria who cannot be given an unlicensed product. GMP AS is currently under development, both in China and in the USA, for treatment of falciparum malaria.
The two available methods used for determining PK parameters of AS and DHA are the compartmental (model-dependent) and non-compartment (model-independent) PK analytical techniques. PK evaluation of IV AS with a short-term IV infusion, however, requires compartmental analysis. When using NCA for AS PK parameter modelling, the AUC calculation for AS will be adversely perturbed due to the loss of accurate assessment of Cmax at the end of the 2-min IV infusion. In previous published reports, the AUC of AS calculated using NCA underestimated the AUC parameter by 28-49% when compared to CA analysis[15, 16]. Similar underestimation of AUC was also shown in this study. Therefore, the CA analysis model is capable of accurately determining the PK parameters of both AS and DHA in this study. For further evaluation of PK modeling of intravenous AS administered by infusion, a specific manuscript is being prepared based on the PK data from three clinical trials utilizing a variety of PK software packages.
In this study and as previously reported, artesunate is rapidly converted to DHA. DHA was detected in all patients’ plasma up to six hours after administration, while the parent drug (AS) was undetectable at time-points as early as one to two hours after each short-term infusion. Although the plasma exposure of DHA was increased when compared to AS with an AUCDHA/AS ratio of 1.94, the peak concentration of AS was shown to be much higher than DHA with a CmaxAS/Cmax DHA ratio of 10.24.
In this study, DHA was shown to have 7.65-fold longer half-life than that of AS. Therefore, the efficacy of AS has been attributed both to its own intrinsic activity and to the activity of its principle metabolite, DHA[2–4]. The high peak concentrations achieved after dosing patients intravenously with AS provides a significant advantage over other anti-malarial drugs to achieve rapid killing of malaria parasites. A number of pharmacokinetic and pharmacodynamic evaluations have shown that the rapid efficacy of artemisinins is principally due to the elevated Cmax achieved after drug administration, and further studies have shown that AS is superior to other artemisinin analogues in terms of the very high Cmax observed following oral or IV administration. Other PK parameters, such as the drug exposure level (AUC), and drug exposure time (half-life) have been shown to be of lesser importance[19, 20]. A number of studies have also shown the rapid pharmacodynamic effects of these drugs in rapidly decreasing the parasite biomass after administration.
The main pharmacokinetic parameters of artesunate (AS) and dihydroartemisinin (DHA) following intravenous (IV) administrations in malaria patients and volunteers
Ratio of AUCDHA/AS
AUC ng · h/mL
AUC ng · h/mL
The dose of intravenous AS currently used for clinical use was designed in accordance with prior experience of physicians over the last 25 years who were concerned with neurotoxicity and dose-dependent haemotoxicity and thus, the dose was limited to 2–2.4 mg/kg to prevent a submaximal anti-malarial effect, and to sustain a minimum curative rate >90%. The lower peak concentrations achieved in some patients, however, especially those who have severe and complicated malaria associated with hyperparasitaemia of >5% may result in clinical failure. In the SEAQUAMAT and AQUAMAT clinical trial studies, IV AS was shown to be superior to quinine, and patients with hyperparasitaemia had a significantly greater treatment response to AS than in patients without hyperparasitaemia[9–12].
In theory, patients with severe malaria require a peak concentration of AS ranging from 7,500-30,000 ng/mL to efficaciously exterminate malaria parasites where parasitaemia exceeds 5%. This calculation is based on the drug concentration achieved at equilibrium after oral AS administration of 1,250 ng/mL (AS plus DHA), which was required to cure patients infected with malaria who had a parasitaemia of 1%. The estimation of patients with severe malaria would require a peak plasma concentration of AS plus DHA at least 7,500 ng/mL to effectively reduce the parasite biomass in patients with severe malaria given previous data and the data from other trials. Accordingly, dosing of AS at 2.0 - 2.4 mg/kg intravenously will likely not satisfactorily distribute an efficacious drug level to every erythrocyte (infected and uninfected) in each patient with hyperparasitaemia. When taking into account the large variability in PK and PD between individuals, a larger dose will be required to ensure that a maximum effect is obtained in all patients. The patients with hyperparasitaemia are effectively treated is to increase the intravenous loading dose to a higher level in the range of 4–8 mg/kg, which should be well tolerated given other studies showing single and multiple injections of AS in volunteers up to a dose of 8 mg/kg dose were exceedingly well tolerated[15, 16]. However, further trials are needed to test this dose and the frequency of IV AS treatments at that dose required to achieve cures of patients with severe malaria patients.
The study presented here underlines the need for appropriate PK analysis of AS and DHA following intravenous infusion. Injectable AS is a superior anti-malarial agent yielding very high peak plasma concentrations over a very short exposure time. The higher peak level serves to eliminate parasites rapidly, and the short exposure time aids in avoiding fatal neurotoxicity. Previous data from other studies have shown that administration of injectable AS at doses up to 8 mg/kg is safe[15, 16], and given the large inter-individual variability associated with AS administration, use of higher doses may increase the probability of success in patients with hyperparasitaemia associated with severe malaria[20, 32].
This study was supported by the US Army Research and Materiel Command. Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official, or as reflecting the views of the Department of the Army or the Department of Defense.
- Skinner TS, Manning LS, Johnston WA, Davis TM: In vitro stage-specific sensitivity of Plasmodium falciparum to quinine and artemisinin drugs. Int J Parasit. 1996, 26: 519-525.View ArticleGoogle Scholar
- Nadjm B, Behrens RH: Malaria: an update for physicians. Infect Dis Clin North Am. 2012, 26: 243-259.View ArticlePubMedGoogle Scholar
- Davis TM, Phuong HL, Ilett KF, Hung NC, Batty KT, Phuong VD, Powell SM, Thien HV, Binh TQ: Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria. Antimicrob Agents Chemother. 2001, 45: 181-186.PubMed CentralView ArticlePubMedGoogle Scholar
- Navaratnam V, Mansor SM, Sit NW, Grace J, Li QG, Olliaro P: Pharmacokinetics of artemisinin-type compounds. Clin Pharmacokinet. 2000, 39: 255-270.View ArticlePubMedGoogle Scholar
- Li Q, Gerena L, Xie L, Zhang J, Kyle D, Milhous W: Development and validation of flow cytometric measurement for parasitemia in cultures of P. falciparum vitally stained with YOYO-1. Cytometry A. 2007, 71A: 297-307.View ArticleGoogle Scholar
- Li QG, Mog SR, Si YZ, Kyle DE, Gettayacamin M, Milhous WK: Neurotoxicity and efficacy of arteether related to its exposure times and exposure levels in rodents. Am J Trop Med Hyg. 2002, 66: 516-525.PubMedGoogle Scholar
- McLean WG, Ward SA: In vitro neurotoxicity of artemisinin derivatives. Med Trop (Mars). 1998, 58 (3 Suppl): 28-31.Google Scholar
- Pasvol G: The treatment of complicated and severe malaria. Br Med Bull. 2006, 75–76: 29-47.View ArticlePubMedGoogle Scholar
- Li Q, Weina PJ: Artesunate: the best drug in the treatments of severe and complicated malaria. Pharmaceuticals. 2010, 3: 2322-2332.PubMed CentralView ArticleGoogle Scholar
- Dondorp A, Nosten F, Stepniewska K, Day N, White N: Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005, 366: 717-725.View ArticlePubMedGoogle Scholar
- Kreeftmeijer-Vegter AR, van Genderen PJ, Visser LG, Bierman WF, Clerinx J, van Veldhuizen CK, de Vries PJ: Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium. Malar J. 2012, 11: 102-PubMed CentralView ArticlePubMedGoogle Scholar
- WHO: Guidelines for the treatment of malaria. 2010, Geneva, Switzerland: World Health Organization,http://www.who.int/malaria/publications/atoz/9789241547925/en/,Google Scholar
- Website title: Safety and Efficacy Study of IV Artesunate to Treat Malaria, ClinicalTrials.gov Identifier: NCT00298610. [http://clinicaltrials.gov/ct2/show/NCT00298610?term=NCT00298610&rank=1]
- Teja-Isavadharm P, Siriyanonda D, Siripokasupkul R, Apinan R, Chanarat N, Lim A, Wannaying S, Saunders D, Fukuda MM, Miller RS, Weina PJ, Meléndez V: A simplified liquid chromatography-mass spectrometry assay for artesunate and dihydroartemisinin, its metabolite, in human plasma. Molecules. 2010, 15: 8747-8768.View ArticlePubMedGoogle Scholar
- Li Q, Cantilena LR, Leary KJ, Saviolakis GA, Miller RS, Melendez V, Weina PJ: Pharmacokinetic profiles of artesunate after single intravenous doses at 0.5, 1, 2, 4, and 8 mg/kg in healthy volunteers: a phase I study. Am J Trop Med Hyg. 2009, 81: 615-621.View ArticlePubMedGoogle Scholar
- Miller RS, Li Q, Cantilena LR, Leary KJ, Saviolakis QA, Melendez V, Smith B, Weina PJ: Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: phase 1b study. Malar J. 2012, 11: 255-PubMed CentralView ArticlePubMedGoogle Scholar
- Hess KM, Goad JA, Arguin PM: Intravenous artesunate for the treatment of severe malaria. Ann Pharmacother. 2010, 44: 1250-1258.View ArticlePubMedGoogle Scholar
- FDA: Guidance for Industry, General considerations for pediatric pharmacokinetic studies for drugs and biological products 1998. 2008, U.S. Food and Drug Administration,http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072114.pdf,Google Scholar
- Li Q, Weina P, Milhous WK: Pharmacokinetic and pharmacodynamic profiles of rapid-acting artemisinins in the antimalarial therapy. Current Drug Therapy. 2007, 2: 210-223.View ArticleGoogle Scholar
- Li Q, Milhous WK, Weina PJ: Antimalarial in malaria therapy. Antimalarial in Malaria Therapy. Edited by: Li Q, Milhous WK, Weina P. 2007, New York: Nova Science Publishers Inc, 70-84.Google Scholar
- Li Q, Lugt CB, Looareesuwan S, Krudsood S, Wilairatana P, Vannaphan S, Chalearmrult K, Milhous WK: Pharmacokinetic investigation on the therapeutic potential of artemotil (beta-arteether) in Thai patients with severe Plasmodium falciparum malaria. Am J Trop Med Hyg. 2004, 71: 723-731.PubMedGoogle Scholar
- Nealon C, Dzeing A, Muller-Romer U, Planche T, Sinou V, Kombila M, Kremsner PG, Parzy D, Krishna S: Intramuscular bioavailability and clinical efficacy of artesunate in gabonese children with severe malaria. Antimicrob Agents Chemother. 2002, 46: 3933-3939.PubMed CentralView ArticlePubMedGoogle Scholar
- Krishna S, Planche T, Agbenyega T, Woodrow C, Agranoff D, Bedu-Addo G, Owusu-Ofori AK, Appiah JA, Ramanathan S, Mansor SM, Navaratnam V: Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. Antimicrob Agents Chemother. 2001, 45: 509-516.PubMed CentralView ArticlePubMedGoogle Scholar
- Batty KT, Thu LT, Davis TM, Ilett KF, Mai TX, Hung NC, Tien NP, Powell SM, Thien HV, Binh TQ, Kim NV: A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. Br J Clin Pharmacol. 1998, 45: 123-129.PubMed CentralView ArticlePubMedGoogle Scholar
- Ilett KF, Batty KT, Powell SM, Binh TQ, le TA T, Phuong HL, Hung NC, Davis TM: The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria. Br J Clin Pharmacol. 2002, 53: 23-30.PubMed CentralView ArticlePubMedGoogle Scholar
- Newton P, Suputtamongkol Y, Teja-Isavadharm P, Pukrittayakamee S, Navaratnam V, Bates I, White N: Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria. Antimicrob Agents Chemother. 2000, 44: 972-977.PubMed CentralView ArticlePubMedGoogle Scholar
- Binh TQ, Ilett KF, Batty KT, Davis TM, Hung NC, Powell SM, Thu LT, Thien HV, Phuong HL, Phuong VD: Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria. Br J Clin Pharmacol. 2001, 51: 541-546.PubMed CentralView ArticlePubMedGoogle Scholar
- Newton PN, Barnes KI, Smith PJ, Evans AC, Chierakul W, Ruangveerayuth R, White NJ: The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria. Eur J Clin Pharmacol. 2006, 62: 1003-1009.View ArticlePubMedGoogle Scholar
- Barradell LB, Fitton A: Artesunate, A review of its pharmacology and therapeutic efficacy in the treatment of malaria. Drugs. 1995, 50: 714-741.View ArticlePubMedGoogle Scholar
- Li Q, Weina PJ: Antimalarial drugs: age of the artemisinins. Edited by: Li Q, Weina PJ. 2010, New York: Nova Science Publishers Inc, 243-328.Google Scholar
- Li Q, Hickman M: Toxicokinetic and toxicodynamic (TK/TD) evaluation to determine and predict the neurotoxicity of artemisinins. Toxicology. 2011, 279: 1-9.View ArticlePubMedGoogle Scholar
- van Hensbroek MB, Onyiorah E, Jaffar S: A trial of artemether or quinine in children with cerebral malaria. N Engl J Med. 1996, 335: 69-75.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.